<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39459978</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Inflammasome-Driven Fatal Acute-on-Chronic Liver Failure Triggered by Mild COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1646</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16101646</ELocationID><Abstract><AbstractText>Inflammasome is linked to many inflammatory diseases, including COVID-19 and autoimmune liver diseases. While severe COVID-19 was reported to exacerbate liver failure, we report a fatal acute-on-chronic liver failure (ACLF) in a stable primary biliary cholangitis-autoimmune hepatitis overlap syndrome patient triggered by a mild COVID-19 infection. Postmortem liver biopsy showed sparse SARS-CoV-2-infected macrophages with extensive ASC (apoptosis-associated speck-like protein containing a CARD) speck-positive hepatocytes, correlating with elevated circulating ASC specks and inflammatory cytokines, and depleted blood monocyte subsets, indicating widespread liver inflammasome activation. This first report of a fatal inflammatory cascade in an autoimmune liver disease triggered by a mild remote viral infection hopes to elucidate a less-described pathophysiology of ACLF that could prompt consideration of new diagnostic and therapeutic options.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Vivian Chih-Wei</ForeName><Initials>VC</Initials><Identifier Source="ORCID">0000-0001-8757-0644</Identifier><AffiliationInfo><Affiliation>Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Craig Ryan</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore 138673, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Wharton O Y</ForeName><Initials>WOY</Initials><Identifier Source="ORCID">0000-0002-4526-470X</Identifier><AffiliationInfo><Affiliation>Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sia</LastName><ForeName>Wan Rong</ForeName><Initials>WR</Initials><Identifier Source="ORCID">0000-0003-2694-4192</Identifier><AffiliationInfo><Affiliation>Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-6556-1261</Identifier><AffiliationInfo><Affiliation>Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sam</LastName><ForeName>Xin Xiu</ForeName><Initials>XX</Initials><AffiliationInfo><Affiliation>Department of Anatomical Pathology, Singapore General Hospital, Singapore 169856, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamilarasan</LastName><ForeName>Hemavathi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore 138673, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mah</LastName><ForeName>Yun Yan</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Wei Lun</ForeName><Initials>WL</Initials><Identifier Source="ORCID">0000-0003-1533-9325</Identifier><AffiliationInfo><Affiliation>Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeong</LastName><ForeName>Joe</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6674-7153</Identifier><AffiliationInfo><Affiliation>Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore 138673, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology &amp; Serology Section, Department of Microbiology, Division of Pathology, Singapore General Hospital, Singapore 169856, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lin-Fa</ForeName><Initials>LF</Initials><Identifier Source="ORCID">0000-0003-2752-0535</Identifier><AffiliationInfo><Affiliation>Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SingHealth Duke-NUS Global Health Institute, Singapore 169857, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnamoorthy</LastName><ForeName>Thinesh L</ForeName><Initials>TL</Initials><Identifier Source="ORCID">0000-0002-5640-1079</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore 169608, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leow</LastName><ForeName>Wei-Qiang</ForeName><Initials>WQ</Initials><Identifier Source="ORCID">0000-0001-6003-9837</Identifier><AffiliationInfo><Affiliation>Department of Anatomical Pathology, Singapore General Hospital, Singapore 169856, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Matae</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2114-8250</Identifier><AffiliationInfo><Affiliation>Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SingHealth Duke-NUS Medicine Academic Clinical Program, Singapore 168753, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SingHealth Internal Medicine Residency Program, Singapore 169608, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Wan Cheng</ForeName><Initials>WC</Initials><Identifier Source="ORCID">0000-0002-7567-999X</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore 169608, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SingHealth Duke-NUS Medicine Academic Clinical Program, Singapore 168753, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOH-000561</GrantID><Agency>Ministry of Health</Agency><Country /></Grant><Grant><GrantID>MOE2019-T2-2-130</GrantID><Agency>Ministry of Education</Agency><Country /></Grant><Grant><GrantID>OFLCG23may-0039</GrantID><Agency>National Medical Research Council</Agency><Country /></Grant><Grant><GrantID>NMRC/OFLCG/002-2018</GrantID><Agency>National Medical Research Council</Agency><Country /></Grant><Grant><GrantID>IAF-ICP I2201E0014</GrantID><Agency>Agency for Science, Technology and Research</Agency><Country /></Grant><Grant><GrantID>IAF-ICP I2001E0065</GrantID><Agency>Agency for Science, Technology and Research</Agency><Country /></Grant><Grant><GrantID>I20AGAG602</GrantID><Agency>Agency for Science, Technology and Research</Agency><Country /></Grant><Grant><GrantID>I23D1AG048</GrantID><Agency>Agency for Science, Technology and Research</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065290" MajorTopicYN="Y">Acute-On-Chronic Liver Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058847" MajorTopicYN="Y">Inflammasomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019693" MajorTopicYN="N">Hepatitis, Autoimmune</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ASC</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">NLRP3</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">acute-on-chronic liver failure</Keyword><Keyword MajorTopicYN="N">autoimmune hepatitis</Keyword><Keyword MajorTopicYN="N">inflammasome</Keyword><Keyword MajorTopicYN="N">primary biliary cholangitis</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459978</ArticleId><ArticleId IdType="pmc">PMC11512379</ArticleId><ArticleId IdType="doi">10.3390/v16101646</ArticleId><ArticleId IdType="pii">v16101646</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guo H., Callaway J.B., Ting J.P.-Y. Inflammasomes: Mechanism of action, role in disease, and therapeutics. Nat. Med. 2015;21:677–687. doi: 10.1038/nm.3893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3893</ArticleId><ArticleId IdType="pmc">PMC4519035</ArticleId><ArticleId IdType="pubmed">26121197</ArticleId></ArticleIdList></Reference><Reference><Citation>Frissen M., Liao L., Schneider K.M., Djudjaj S., Haybaek J., Wree A., Rolle-Kampczyk U., von Bergen M., Latz E., Boor P., et al. Bidirectional role of NLRP3 during acute and chronic cholestatic liver injury. Hepatology. 2021;73:1836–1854. doi: 10.1002/hep.31494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.31494</ArticleId><ArticleId IdType="pubmed">32748971</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi F.-L., Ni S.-T., Luo S.-Q., Hu B., Xu R., Liu S.-Y., Huang X.-D., Zeng B., Liang Q.-Q., Chen S.-Y., et al. Dimethyl fumarate ameliorates autoimmune hepatitis in mice by blocking NLRP3 inflammasome activation. Int. Immunopharmacol. 2022;108:108867. doi: 10.1016/j.intimp.2022.108867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.108867</ArticleId><ArticleId IdType="pubmed">35605433</ArticleId></ArticleIdList></Reference><Reference><Citation>Sefik E., Qu R., Junqueira C., Kaffe E., Mirza H., Zhao J., Brewer J.R., Han A., Steach H.R., Israelow B., et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature. 2022;606:585–593. doi: 10.1038/s41586-022-04802-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04802-1</ArticleId><ArticleId IdType="pmc">PMC9288243</ArticleId><ArticleId IdType="pubmed">35483404</ArticleId></ArticleIdList></Reference><Reference><Citation>Junqueira C., Crespo A., Ranjbar S., de Lacerda L.B., Lewandrowski M., Ingber J., Parry B., Ravid S., Clark S., Schrimpf M.R., et al. FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature. 2022;606:576–584. doi: 10.1038/s41586-022-04702-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04702-4</ArticleId><ArticleId IdType="pmc">PMC10071495</ArticleId><ArticleId IdType="pubmed">35385861</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjot T., Webb G.J., Barritt IV A.S., Moon A.M., Stamataki Z., Wong V.W., Barnes E. COVID-19 and liver disease: Mechanistic and clinical perspectives. Nat. Rev. Gastroenterol. Hepatol. 2021;18:348–364. doi: 10.1038/s41575-021-00426-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-021-00426-4</ArticleId><ArticleId IdType="pmc">PMC7945972</ArticleId><ArticleId IdType="pubmed">33692570</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J.C.T., Yeong J.P.S., Lim C.J., Ong C.C.H., Wong S.C., Chew V.S.P., Ahmed S.S., Tan P.H., Iqbal J. An automated staining protocol for seven-colour immunofluorescence of human tissue sections for diagnostic and prognostic use. Pathology. 2018;50:333–341. doi: 10.1016/j.pathol.2017.11.087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pathol.2017.11.087</ArticleId><ArticleId IdType="pubmed">29429740</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeong J., Thike A.A., Lim J.C.T., Lee B., Li H., Wong S.-C., Hue S.S.S., Tan P.H., Iqbal J. Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer. Breast Cancer Res. Treat. 2017;163:21–35. doi: 10.1007/s10549-017-4161-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-017-4161-4</ArticleId><ArticleId IdType="pubmed">28233108</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeong J., Lim J.C.T., Lee B., Li H., Ong C.C.H., Thike A.A., Yeap W.H., Yang Y., Lim A.Y.H., Tay T.K.Y., et al. Prognostic value of CD8+ PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer. J. Immunother. Cancer. 2019;7:34. doi: 10.1186/s40425-019-0499-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-019-0499-y</ArticleId><ArticleId IdType="pmc">PMC6366051</ArticleId><ArticleId IdType="pubmed">30728081</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeong J., Lim J.C.T., Lee B., Li H., Chia N., Ong C.C.H., Lye W.K., Putti T.C., Dent R., Lim E., et al. High densities of tumor-associated plasma cells predict improved prognosis in triple negative breast cancer. Front. Immunol. 2018;9:338674. doi: 10.3389/fimmu.2018.01209.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01209</ArticleId><ArticleId IdType="pmc">PMC5988856</ArticleId><ArticleId IdType="pubmed">29899747</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng H.H.M., Lee R.Y., Goh S., Tay I.S.Y., Lim X., Lee B., Chew V., Li H., Tan B., Lim S., et al. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. J. Immunother. Cancer. 2020;8:e000987. doi: 10.1136/jitc-2020-000987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-000987</ArticleId><ArticleId IdType="pmc">PMC7451957</ArticleId><ArticleId IdType="pubmed">32847986</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A., Davis C.A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Batut P., Chaisson M., Gingeras T. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21. doi: 10.1093/bioinformatics/bts635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y., Smyth G.K., Shi W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 2019;47:e47. doi: 10.1093/nar/gkz114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz114</ArticleId><ArticleId IdType="pmc">PMC6486549</ArticleId><ArticleId IdType="pubmed">30783653</ArticleId></ArticleIdList></Reference><Reference><Citation>Govaere O., Cockell S., Tiniakos D., Queen R., Younes R., Vacca M., Alexander L., Ravaioli F., Palmer J., Petta S., et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci. Transl. Med. 2020;12:eaba4448. doi: 10.1126/scitranslmed.aba4448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aba4448</ArticleId><ArticleId IdType="pubmed">33268509</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews T.S., Nakib D., Perciani C.T., Ma X.Z., Liu L., Winter E., Camat D., Chung S.W., Lumanto P., Manuel J., et al. Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver. J. Hepatol. 2024;80:730–743. doi: 10.1016/j.jhep.2023.12.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2023.12.023</ArticleId><ArticleId IdType="pubmed">38199298</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson M.D., McCarthy D.J., Smyth G.K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–140. doi: 10.1093/bioinformatics/btp616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp616</ArticleId><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Selitsky S.R., Marron D., Hollern D., Mose L.E., Hoadley K.A., Jones C., Parker J.S., Dittmer D.P., Perou C.M. Virus expression detection reveals RNA-sequencing contamination in TCGA. BMC Genom. 2020;21:79. doi: 10.1186/s12864-020-6483-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12864-020-6483-6</ArticleId><ArticleId IdType="pmc">PMC6986043</ArticleId><ArticleId IdType="pubmed">31992194</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahne F., Ivanek R. Visualizing Genomic Data Using Gviz and Bioconductor. In: Mathé E., Davis S., editors. Statistical Genomics: Methods and Protocols. Volume 1418. Humana Press; New York, NY, USA: 2016. pp. 335–351.</Citation><ArticleIdList><ArticleId IdType="pubmed">27008022</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham H. ggplot2: Elegant Graphics for Data Analysis. 2nd ed. Springer Cham; Berlin/Heidelberg, Germany: 2016. pp. 189–201.</Citation></Reference><Reference><Citation>Pan P., Shen M., Yu Z., Ge W., Chen K., Tian M., Xiao F., Wang Z., Wang J., Jia Y., et al. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. Nat. Commun. 2021;12:4664. doi: 10.1038/s41467-021-25015-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25015-6</ArticleId><ArticleId IdType="pmc">PMC8329225</ArticleId><ArticleId IdType="pubmed">34341353</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang T., Lee J.P.W., Elgass K., Pinar A.A., Tate M.D., Aitken E.H., Fan H., Creed S.J., Deen D.S., Traore D.A.K., et al. Macrophage migration inhibitory factor is required for NLRP3 inflammasome activation. Nat. Commun. 2018;9:2223. doi: 10.1038/s41467-018-04581-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04581-2</ArticleId><ArticleId IdType="pmc">PMC5993818</ArticleId><ArticleId IdType="pubmed">29884801</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.W., Chia W.N., Qin X., Liu P., Chen M.I.-C., Tiu C., Hu Z., Chen V.C.-W., Young B.E., Sia W.R., et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nat. Biotechnol. 2020;38:1073–1078. doi: 10.1038/s41587-020-0631-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0631-z</ArticleId><ArticleId IdType="pubmed">32704169</ArticleId></ArticleIdList></Reference><Reference><Citation>Albillos A., Lario M., Álvarez-Mon M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance. J. Hepatol. 2014;61:1385–1396. doi: 10.1016/j.jhep.2014.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2014.08.010</ArticleId><ArticleId IdType="pubmed">25135860</ArticleId></ArticleIdList></Reference><Reference><Citation>Baroja-Mazo A., Martín-Sánchez F., Gomez A.I., Martínez C.M., Amores-Iniesta J., Compan V., Barberà-Cremades M., Yagüe J., Ruiz-Ortiz E., Antón J., et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat. Immunol. 2014;15:738–748. doi: 10.1038/ni.2919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2919</ArticleId><ArticleId IdType="pubmed">24952504</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullaro G., Sharma R., Trebicka J., Cárdenas A., Verna E.C. Precipitants of Acute-on-Chronic Liver Failure: An Opportunity for Preventative Measures to Improve Outcomes. Liver Transpl. 2020;26:283–293. doi: 10.1002/lt.25678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lt.25678</ArticleId><ArticleId IdType="pmc">PMC8046290</ArticleId><ArticleId IdType="pubmed">31714011</ArticleId></ArticleIdList></Reference><Reference><Citation>Schütte A., Ciesek S., Wedemeyer H., Lange C.M. Influenza virus infection as precipitating event of acute-on-chronic liver failure. J. Hepatol. 2019;70:797–799. doi: 10.1016/j.jhep.2018.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2018.11.015</ArticleId><ArticleId IdType="pubmed">30635243</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaccherini G., Weiss E., Moreau R. Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment. JHEP Rep. 2021;3:100176. doi: 10.1016/j.jhepr.2020.100176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhepr.2020.100176</ArticleId><ArticleId IdType="pmc">PMC7652714</ArticleId><ArticleId IdType="pubmed">33205036</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A., Zlitni S., Brooks E.F., Vance S.E., Dahlen A., Hedlin H., Park R.M., Han A., Schmidtke D.T., Verma R., et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med. 2022;3:371–387.e9. doi: 10.1016/j.medj.2022.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Xiao J., Sun R., Tang X., Liang C., Lin H., Zeng L., Hu J., Zhou P., Peng J., et al. Prolonged Persistence of SARS-CoV-2 RNA in Body Fluids. Emerg. Infect. Dis. 2020;26:1834–1838. doi: 10.3201/eid2608.201097.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2608.201097</ArticleId><ArticleId IdType="pmc">PMC7392422</ArticleId><ArticleId IdType="pubmed">32383638</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues T.S., de Sá K.S.G., Ishimoto A.Y., Becerra A., Oliveira S., Almeida L., Gonçalves A.V., Perucello D.B., Andrade W.A., Castro R., et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J. Exp. Med. 2020;218:e20201707. doi: 10.1084/jem.20201707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201707</ArticleId><ArticleId IdType="pmc">PMC7684031</ArticleId><ArticleId IdType="pubmed">33231615</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinen N., Khanal R., Westhoven S., Klöhn M., Herrmann S.T., Herrmann M., Tuoc T., Ulmke P.A., Nguyen H.D., Nguyen H.P., et al. Productive infection of primary human hepatocytes with SARS-CoV-2 induces antiviral and proinflammatory responses. Gut. 2023;73:e14. doi: 10.1136/gutjnl-2023-330961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2023-330961</ArticleId><ArticleId IdType="pmc">PMC11420759</ArticleId><ArticleId IdType="pubmed">38123990</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty S., Gonzalez J., Edwards K., Mallajosyula V., Buzzanco A.S., Sherwood R., Buffone C., Kathale N., Providenza S., Xie M.M., et al. Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat. Immunol. 2021;22:67–73. doi: 10.1038/s41590-020-00828-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00828-7</ArticleId><ArticleId IdType="pmc">PMC8130642</ArticleId><ArticleId IdType="pubmed">33169014</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun P., Zhong J., Liao H., Loughran P., Mulla J., Fu G., Tang D., Fan J., Billiar T.R., Gao W., et al. Hepatocytes are resistant to cell death from canonical and non-canonical inflammasome-activated pyroptosis. Cell. Mol. Gastroenterol. Hepatol. 2022;13:739–757. doi: 10.1016/j.jcmgh.2021.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmgh.2021.11.009</ArticleId><ArticleId IdType="pmc">PMC8783146</ArticleId><ArticleId IdType="pubmed">34890842</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai S.Y., Ouyang X., Chen Y., Soroka C.J., Wang J., Mennone A., Wang Y., Mehal W.Z., Jain D., Boyer J.L. Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response. JCI Insight. 2017;2:e90780. doi: 10.1172/jci.insight.90780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.90780</ArticleId><ArticleId IdType="pmc">PMC5333973</ArticleId><ArticleId IdType="pubmed">28289714</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmann T.M., Inzaugarat M.E., Knorr J., Geisler L., Schulz M., Bieghs V., Frissen M., Feldstein A.E., Tacke F., Trautwein C., et al. Bile Acids Activate NLRP3 Inflammasome, Promoting Murine Liver Inflammation or Fibrosis in a Cell Type-Specific Manner. Cells. 2021;10:2618. doi: 10.3390/cells10102618.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10102618</ArticleId><ArticleId IdType="pmc">PMC8534222</ArticleId><ArticleId IdType="pubmed">34685598</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn M., Chen V.C.-W., Rozario P., Ng W.L., Kong P.S., Sia W.R., Kang A.E.Z., Su Q., Nguyen L.H., Zhu F., et al. Bat ASC2 suppresses inflammasomes and ameliorates inflammatory diseases. Cell. 2023;186:2144–2159.e22. doi: 10.1016/j.cell.2023.03.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.03.036</ArticleId><ArticleId IdType="pubmed">37172565</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>